This study is designed to test the hypothesis that the intramuscular administration of 10 IU of oxytocin in Uniject™ during the third stage of labor by a Community Health Officer (CHO) at home births in Ghana will reduce the risk of postpartum hemorrhage by 50 percent relative to home births attended by the same type of provider who does not provide a uterotonic drug.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,586
10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
Kintampo Health Research Center
Kintampo, Brong Ahafo, Ghana
postpartum hemorrhage-1
blood loss \>=500 ml after delivery of the baby, as measured through plastic calibrated drape
Time frame: after delivery of baby
postpartum hemorrhage-2
blood loss \>=500ml OR treatment dose of oxytocin provided
Time frame: after delivery of the baby
postpartum hemorrhage-3
blood loss \>=500ml OR treatment dose of oxytocin provided OR referral for bleeding
Time frame: after delivery of the baby
Oxytocin use before delivery
the proportion of deliveries where oxytocin in uniject was administered prior to the delivery of the baby
Time frame: labor and delivery
stillbirth
stillbirth is defined as death of a fetus after 28 weeks of gestation, prior to birth
Time frame: labor/delivery
neonatal death
neonatal death is defined as death of a live born baby prior to completion of 28 days
Time frame: first month of life
need for neonatal resuscitation
Time frame: 0-6 hours after birth
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.